Literature DB >> 9448989

Drugs associated with vasculitis.

P A Merkel1.   

Abstract

Newer agents of particular interest to rheumatologists are increasingly associated with vasculitis. There is now good evidence that treatment with hematopoietic growth factors, including granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, can cause or mimic vasculitides such as Sweet's syndrome and pyoderma gangrenosum. Similarly, there is strong evidence that clinical use of interferons is associated with a variety of autoimmune phenomenon rarely including vasculitis. The increased availability of testing for antineutrophil cytoplasmic antibody (ANCA) has widened the clinical spectrum of systemic vasculitides. There are now many reports that treatment with either hydralazine or propylthiouracil is associated with ANCA-positive vasculitis. A small number of case reports also implicate penicillamine and minocycline as agents capable of inducing an ANCA-associated vasculitis. Clinicians should be aware of the potential of certain drugs to cause vasculitis and especially cautious in using these agents in patients with known vasculitis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9448989     DOI: 10.1097/00002281-199801000-00007

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  15 in total

Review 1.  Clinical value of antineutrophil cytoplasmic antibodies.

Authors:  V Rus; B S Handwerger
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  Clinical utility of testing for antineutrophil cytoplasmic antibodies.

Authors:  D Vassilopoulos; G S Hoffman
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

3.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) but not granulocyte colony-stimulating factor (G-CSF) induces plasma membrane expression of proteinase 3 (PR3) on neutrophils in vitro.

Authors:  B Hellmich; E Csernok; A Trabandt; W L Gross; M Ernst
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

4.  Peroxiredoxin 2 is a novel autoantigen for anti-endothelial cell antibodies in systemic vasculitis.

Authors:  R Karasawa; M S Kurokawa; K Yudoh; K Masuko; S Ozaki; T Kato
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

5.  ANCA positive propylthiouracil induced pyoderma gangrenosum.

Authors:  K Gungor; S Gonen; G Kisakol; O Dikbas; A Kaya
Journal:  J Endocrinol Invest       Date:  2006-06       Impact factor: 4.256

6.  Antineutrophil cytoplasmic antibody-positive vasculitis associated with propylthiouracil therapy.

Authors:  S Dinmezel; C Ogus; T Ozdemir
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

Review 7.  Controversies in the management of Graves' disease in children.

Authors:  S A Rivkees
Journal:  J Endocrinol Invest       Date:  2016-05-06       Impact factor: 4.256

8.  Covalent modification of proteins by cocaine.

Authors:  Shi-Xian Deng; Narine Bharat; Marian C Fischman; Donald W Landry
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-12       Impact factor: 11.205

Review 9.  ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review.

Authors:  Petar Lenert; Michael Icardi; Laila Dahmoush
Journal:  Clin Rheumatol       Date:  2013-04-21       Impact factor: 2.980

10.  Systemic and Central Nervous System Vasculitides.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.